Moderna (MRNA) Net Income Quarterly: History & Chart

Moderna, Inc.(MRNA)

Biotechnology · Cambridge, MA

$145.55-3.32 (-2.23%)

Delayed quote: Sep 4, 2026, 4:00 PM EDT

About Moderna, Inc.

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Cambridge, MA

4,700 employees

www.modernatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Stéphane Bancel

View full financials

Quarterly Net Income

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly quarterly net income is ($782.00M). Quarterly net income is profit after expenses, taxes, interest, and other items for the latest fiscal quarter.

Net Income TTM|Net Income CAGR|Profit Margin|Financials

Quarterly Net Income

MRNA Quarterly Net Income

$-782.00M

Reported quarterly net income; no daily interpolation.

-876.58% over 10Y

MRNA P/E Ratio

Full P/E Ratio page

P/E Ratio

MRNA P/E Ratio Chart

26.09

+475.94% 1Y

MRNA Earnings Yield

Full Earnings Yield page

Earnings Yield

MRNA Earnings Yield Chart

3.83%

-82.65% 1Y

Quarterly Net Income History

Period	Quarterly Net Income	% Change
Quarter ended Jun 2026	($782.00M)	N/A
Quarter ended Mar 2026	($1.34B)	N/A
Quarter ended Dec 2025	($826.00M)	N/A
Quarter ended Sep 2025	($200.00M)	N/A
Quarter ended Jun 2025	($825.00M)	N/A
Quarter ended Mar 2025	($971.00M)	N/A
Quarter ended Dec 2024	($1.12B)	N/A
Quarter ended Sep 2024	$13.00M	N/A
Quarter ended Jun 2024	($1.28B)	N/A
Quarter ended Mar 2024	($1.18B)	(641.47%)
Quarter ended Dec 2023	$217.00M	N/A
Quarter ended Sep 2023	($3.63B)	N/A
Quarter ended Jun 2023	($1.38B)	N/A
Quarter ended Mar 2023	$79.00M	(94.61%)
Quarter ended Dec 2022	$1.47B	+40.46%
Quarter ended Sep 2022	$1.04B	(52.53%)
Quarter ended Jun 2022	$2.20B	(39.92%)
Quarter ended Mar 2022	$3.66B	(24.88%)
Quarter ended Dec 2021	$4.87B	+46.05%
Quarter ended Sep 2021	$3.33B	+19.89%
Quarter ended Jun 2021	$2.78B	+127.68%
Quarter ended Mar 2021	$1.22B	N/A
Quarter ended Dec 2020	($272.49M)	N/A
Quarter ended Sep 2020	($233.64M)	N/A
Quarter ended Jun 2020	($116.71M)	N/A
Quarter ended Mar 2020	($124.23M)	N/A
Quarter ended Dec 2019	($123.29M)	N/A
Quarter ended Sep 2019	($123.19M)	N/A
Quarter ended Jun 2019	($135.05M)	N/A
Quarter ended Mar 2019	($132.58M)	N/A
Quarter ended Dec 2018	($141.43M)	N/A
Quarter ended Sep 2018	($80.33M)	N/A
Quarter ended Jun 2018	($90.60M)	N/A
Quarter ended Mar 2018	($72.38M)	N/A
Quarter ended Dec 2017	($37.94M)	N/A
Quarter ended Sep 2017	($68.26M)	N/A
Quarter ended Jun 2017	($80.08M)	N/A
Quarter ended Mar 2017	($80.08M)	N/A